From 2017 to 2019, the number of beneficiaries prescribed at least 1 oral TKI increased from 154 beneficiaries to 212 beneficiaries.
The post Use of Oral Tyrosine Kinase Inhibitors for R/R CML Increasing Over Time appeared first on Cancer Therapy Advisor.